Lowering NT-proBNP and systolic PA-pressure levels indicate these vasodilators may reduce PAP and cardiac load in COPD patients with PH and further may inhibit the synthesis and secretion of endothelin and pulmonary vascular remodeling. This evidence concerns the gene NPPB and chronic obstructive pulmonary disease.